Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Timber Pharmaceuticals Inc (TMBR)

Timber Pharmaceuticals Inc (TMBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,176
  • Shares Outstanding, K 3,433
  • Annual Sales, $ 80 K
  • Annual Income, $ -19,380 K
  • 60-Month Beta 0.03
  • Price/Sales 14.07
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade TMBR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.11
  • Most Recent Earnings $-1.27 on 08/21/23
  • Next Earnings Date 12/04/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3202 +10.31%
on 11/28/23
2.8737 -87.71%
on 10/30/23
-2.3518 (-86.94%)
since 10/27/23
3-Month
0.3202 +10.31%
on 11/28/23
3.2500 -89.13%
on 08/30/23
-2.8868 (-89.10%)
since 08/29/23
52-Week
0.3202 +10.31%
on 11/28/23
3.3900 -89.58%
on 02/28/23
-1.0068 (-74.03%)
since 11/28/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CTG : 10.50 (+0.10%)
ESTE : 21.17 (+0.47%)
PR : 16.32 (+1.37%)
TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals’ (NYSE American: TMBR) Phase 3 ASCEND Study for TMB-001: A Leap Forward in Congenital Ichthyosis Treatment

Significant Progress in Timber Pharmaceuticals' Phase 3 ASCEND Study Timber Pharmaceuticals (NYSE American: TMBR), a clinical-stage biopharmaceutical company specializing in

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals (NYSE American: TMBR) Granted Orphan Drug Designation in Europe for TMB-001

Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is engaged as a clinical-stage biopharmaceutical company, which is focused on the development and

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR),...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada,...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31, 2022 (GLOBE NEWSWIRE) -- via...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis

Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days BASKING RIDGE, NJ, April 28, 2022 (GLOBE...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results

Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 BASKING RIDGE, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting

Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE, NJ,...

TMBR : 0.3426 (+0.74%)

Business Summary

Timber Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company is initially engaged on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, tuberous...

See More

Key Turning Points

3rd Resistance Point 0.3848
2nd Resistance Point 0.3674
1st Resistance Point 0.3550
Last Price 0.3426
1st Support Level 0.3252
2nd Support Level 0.3078
3rd Support Level 0.2954

See More

52-Week High 3.3900
Fibonacci 61.8% 2.2173
Fibonacci 50% 1.8551
Fibonacci 38.2% 1.4929
Last Price 0.3426
52-Week Low 0.3202

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar